-New members bring expertise in broad range of perspectives, including bioethics, patient advocacy, policy, and clinical practice-
Boston, Mass., March 15, 2017 – The Institute for Clinical and Economic Review (ICER) has appointed new members to each of its three independent evidence appraisal councils: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC).
The new members join the councils of regionally-based experts who represent a broad range of perspectives including medical ethics, outcomes research, health economics, technology assessment, patient advocacy and engagement, and clinical practice. Council members are chosen based on their expertise in reviewing and applying medical evidence in a variety of contexts and are not selected based on their specific expertise in a given clinical area.
The newest members of each of the panels include:
- Felicia Cohn, PhD
Bioethics Director, Kaiser Permanente, Orange County
Clinical Professor of Bioethics, University of California, Irvine School of Medicine
- Jeffrey Hoch, PhD
Professor, Department of Public Health Sciences
Associate Director, Center for Healthcare Policy and Research
University of California, Davis
- Patricia Powers, MPA
Executive Director, Center for Healthcare Decisions
- William Remak, BSc MT, BPH
Emeritus Board Member, California Chronic Care Coalition
- William P. Moore, PhD
Vice President of Program and Evaluation, REACH Healthcare Foundation
- Rachel Sachs, JD, MPH
Associate Professor of Law, Washington University in St. Louis Faculty Scholar, Washington University in St. Louis Institute for Public Health
New England CEPAC
- Brian P. O’Sullivan, MD
Professor of Pediatrics, Geisel School of Medicine at Dartmouth College
Information about upcoming meetings for each program is available on the ICER website.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.